cbdMD Posts 19% Revenue Jump After Bluebird Botanicals Acquisition
The CBD company’s wholesale channel surged 65% year-over-year as the newly acquired Bluebird brand turned profitable in March.
By CBDWorldNews Editorial Staff | May 15, 2026
cbdMD Inc. (NYSE American: YCBD) reported net sales of $5.6 million for the second quarter of fiscal year 2026, marking a 19% increase over the same period last year and a 12% sequential gain from Q1. The results come as the company absorbs its January acquisition of Bluebird Botanicals and positions itself for a new federal healthcare channel.
Bluebird Starts Pulling Its Weight
cbdMD closed the Bluebird Botanicals acquisition in mid-January, adding a respected 10-year-old brand to its portfolio. The integration created short-term drag on earnings — transition costs and duplicated operations weighed on the quarter — but the math began to shift in March, when Bluebird started generating positive income.
The deal was structured as an asset acquisition, giving cbdMD access to Bluebird’s product formulations, customer base, and retail relationships without taking on legacy liabilities. Management indicated during the earnings call that Bluebird should contribute meaningfully to both revenue and profit in coming quarters.
Wholesale Channel Surges
The standout number in the report was wholesale growth: up 65% year-over-year. Wholesale now accounts for roughly 33% of total revenue, up from a smaller share in prior quarters. Direct-to-consumer remained the dominant channel at approximately 67% of sales, but the wholesale expansion signals growing retail distribution.
The shift matters because it suggests cbdMD is moving beyond its roots as a primarily online brand. Adding Bluebird’s existing wholesale accounts likely contributed to the jump, though the company also pointed to organic growth in retail partnerships.
“Bluebird began generating positive income in March. We expect it to be a meaningful contributor to both revenue and earnings going forward.”
The Medicare Angle
Beyond traditional retail, cbdMD has been positioning itself for a first-of-its-kind opportunity: the CMS Substance Access Beneficiary Engagement Incentive. Activated on April 1, the program allows participating Medicare accountable care organizations and oncology practices to furnish qualifying hemp-derived CBD products to patients at up to $500 per beneficiary annually.
cbdMD launched a dedicated clinical healthcare channel to support this pathway, making it one of the first CBD companies to pursue Medicare-adjacent distribution. The program is limited — it operates within specific CMS Innovation Center models rather than broad Medicare coverage — but it represents a significant legitimacy milestone for the CBD industry.
Products must meet strict specifications: non-intoxicating, full-spectrum, containing no more than 3 milligrams of naturally occurring THC per serving, and no synthetic or inhalable products.
Consolidation as Strategy
The acquisition fits a broader pattern in the CBD industry: larger operators buying established brands at favorable valuations. Years of oversupply, regulatory uncertainty, and price compression forced many companies to close or sell. For buyers with capital and patience, the environment has created opportunities.
cbdMD’s approach — acquiring Bluebird’s assets rather than the entire company — reflects lessons learned from earlier CBD M&A deals that saddled acquirers with debt and operational headaches.
For a closer look at how cbdMD and Bluebird products compare to other market leaders, check our brand comparison reviews on CBDProducts.com. The growing intersection of CBD and pet wellness is also driving industry consolidation, a trend we track at CBDPet.com.
Looking Ahead
cbdMD faces the same regulatory uncertainty hanging over the entire hemp-derived products market. The November 12 federal ban on intoxicating hemp products could reshape the competitive landscape, though non-intoxicating CBD products like those in cbdMD’s core line should remain legal.
The company’s bet: that regulatory pressure will clear out weaker competitors while its diversified revenue streams — DTC, wholesale, and now healthcare — provide enough runway to weather the transition.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.
